+

WO2001055307A8 - Acides nucleiques, proteines et anticorps - Google Patents

Acides nucleiques, proteines et anticorps

Info

Publication number
WO2001055307A8
WO2001055307A8 PCT/US2001/001306 US0101306W WO0155307A8 WO 2001055307 A8 WO2001055307 A8 WO 2001055307A8 US 0101306 W US0101306 W US 0101306W WO 0155307 A8 WO0155307 A8 WO 0155307A8
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
antibodies
further relates
present
novel
Prior art date
Application number
PCT/US2001/001306
Other languages
English (en)
Other versions
WO2001055307A3 (fr
WO2001055307A2 (fr
Inventor
Craig A Rosen
Steven C Barash
Steven M Ruben
Original Assignee
Human Genome Sciences Inc
Craig A Rosen
Steven C Barash
Steven M Ruben
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Craig A Rosen, Steven C Barash, Steven M Ruben filed Critical Human Genome Sciences Inc
Priority to EP01908611A priority Critical patent/EP1261633A2/fr
Priority to AU2001236459A priority patent/AU2001236459A1/en
Publication of WO2001055307A2 publication Critical patent/WO2001055307A2/fr
Publication of WO2001055307A8 publication Critical patent/WO2001055307A8/fr
Publication of WO2001055307A3 publication Critical patent/WO2001055307A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne de nouvelles protéines. Plus spécifiquement, l'invention concerne des molécules d'acide nucléique isolées, codant pour de nouveaux polypeptides. Cette invention concerne également : de nouveaux polypeptides et anticorps qui se lient à ces polypeptides ; des vecteurs, des cellules hôtes, et des procédés de recombinaison et de synthèse permettant de produire des polynucléotides et/ou polypeptides humains, et des anticorps ; des procédés diagnostiques et thérapeutiques utiles pour le diagnostic, le traitement, la prévention et/ou la prévision de troubles liés à ces nouveaux polypeptides ; des procédés de criblage permettant d'identifier des agonistes et des antagonistes de polynucléotides et polypeptides de l'invention ; des procédés et/ou des compositions permettant d'inhiber ou d'augmenter la production et la fonctionnalité des polypeptides de la présente invention.
PCT/US2001/001306 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps WO2001055307A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01908611A EP1261633A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
AU2001236459A AU2001236459A1 (en) 2000-01-31 2001-01-17 Nucleic acids, proteins, and antibodies

Applications Claiming Priority (235)

Application Number Priority Date Filing Date Title
US17906500P 2000-01-31 2000-01-31
US60/179,065 2000-01-31
US18062800P 2000-02-04 2000-02-04
US60/180,628 2000-02-04
US18466400P 2000-02-24 2000-02-24
US60/184,664 2000-02-24
US18635000P 2000-03-02 2000-03-02
US60/186,350 2000-03-02
US18987400P 2000-03-16 2000-03-16
US60/189,874 2000-03-16
US19007600P 2000-03-17 2000-03-17
US60/190,076 2000-03-17
US19812300P 2000-04-18 2000-04-18
US60/198,123 2000-04-18
US20551500P 2000-05-19 2000-05-19
US60/205,515 2000-05-19
US20946700P 2000-06-07 2000-06-07
US60/209,467 2000-06-07
US21488600P 2000-06-28 2000-06-28
US60/214,886 2000-06-28
US21513500P 2000-06-30 2000-06-30
US60/215,135 2000-06-30
US21688000P 2000-07-07 2000-07-07
US21664700P 2000-07-07 2000-07-07
US60/216,880 2000-07-07
US60/216,647 2000-07-07
US21748700P 2000-07-11 2000-07-11
US21749600P 2000-07-11 2000-07-11
US60/217,487 2000-07-11
US60/217,496 2000-07-11
US21829000P 2000-07-14 2000-07-14
US60/218,290 2000-07-14
US22096400P 2000-07-26 2000-07-26
US22096300P 2000-07-26 2000-07-26
US60/220,963 2000-07-26
US60/220,964 2000-07-26
US22526700P 2000-08-14 2000-08-14
US22575700P 2000-08-14 2000-08-14
US22521300P 2000-08-14 2000-08-14
US22526800P 2000-08-14 2000-08-14
US22544700P 2000-08-14 2000-08-14
US22521400P 2000-08-14 2000-08-14
US22575800P 2000-08-14 2000-08-14
US22526600P 2000-08-14 2000-08-14
US22451800P 2000-08-14 2000-08-14
US22451900P 2000-08-14 2000-08-14
US22575900P 2000-08-14 2000-08-14
US22527000P 2000-08-14 2000-08-14
US60/225,266 2000-08-14
US60/225,268 2000-08-14
US60/224,518 2000-08-14
US60/225,214 2000-08-14
US60/225,759 2000-08-14
US60/225,758 2000-08-14
US60/225,270 2000-08-14
US60/225,447 2000-08-14
US60/225,267 2000-08-14
US60/225,757 2000-08-14
US60/225,213 2000-08-14
US60/224,519 2000-08-14
US22627900P 2000-08-18 2000-08-18
US60/226,279 2000-08-18
US22668100P 2000-08-22 2000-08-22
US22718200P 2000-08-22 2000-08-22
US22686800P 2000-08-22 2000-08-22
US60/226,868 2000-08-22
US60/226,681 2000-08-22
US60/227,182 2000-08-22
US22700900P 2000-08-23 2000-08-23
US60/227,009 2000-08-23
US22892400P 2000-08-30 2000-08-30
US60/228,924 2000-08-30
US22928700P 2000-09-01 2000-09-01
US22934300P 2000-09-01 2000-09-01
US22934500P 2000-09-01 2000-09-01
US22934400P 2000-09-01 2000-09-01
US60/229,343 2000-09-01
US60/229,287 2000-09-01
US60/229,344 2000-09-01
US60/229,345 2000-09-01
US22951300P 2000-09-05 2000-09-05
US22950900P 2000-09-05 2000-09-05
US60/229,509 2000-09-05
US60/229,513 2000-09-05
US23043800P 2000-09-06 2000-09-06
US23043700P 2000-09-06 2000-09-06
US60/230,438 2000-09-06
US60/230,437 2000-09-06
US23124300P 2000-09-08 2000-09-08
US23208100P 2000-09-08 2000-09-08
US23124200P 2000-09-08 2000-09-08
US23141400P 2000-09-08 2000-09-08
US23124400P 2000-09-08 2000-09-08
US23141300P 2000-09-08 2000-09-08
US23208000P 2000-09-08 2000-09-08
US60/231,244 2000-09-08
US60/231,243 2000-09-08
US60/232,081 2000-09-08
US60/232,080 2000-09-08
US60/231,414 2000-09-08
US60/231,413 2000-09-08
US60/231,242 2000-09-08
US23196800P 2000-09-12 2000-09-12
US60/231,968 2000-09-12
US23306300P 2000-09-14 2000-09-14
US23240000P 2000-09-14 2000-09-14
US23306400P 2000-09-14 2000-09-14
US23239900P 2000-09-14 2000-09-14
US23240100P 2000-09-14 2000-09-14
US23239700P 2000-09-14 2000-09-14
US23306500P 2000-09-14 2000-09-14
US23239800P 2000-09-14 2000-09-14
US60/232,401 2000-09-14
US60/233,064 2000-09-14
US60/233,063 2000-09-14
US60/233,065 2000-09-14
US60/232,397 2000-09-14
US60/232,400 2000-09-14
US60/232,398 2000-09-14
US60/232,399 2000-09-14
US23422300P 2000-09-21 2000-09-21
US23427400P 2000-09-21 2000-09-21
US60/234,223 2000-09-21
US60/234,274 2000-09-21
US23499700P 2000-09-25 2000-09-25
US23499800P 2000-09-25 2000-09-25
US60/234,998 2000-09-25
US60/234,997 2000-09-25
US23548400P 2000-09-26 2000-09-26
US60/235,484 2000-09-26
US23583600P 2000-09-27 2000-09-27
US23583400P 2000-09-27 2000-09-27
US60/235,836 2000-09-27
US60/235,834 2000-09-27
US23632700P 2000-09-29 2000-09-29
US23636700P 2000-09-29 2000-09-29
US23636800P 2000-09-29 2000-09-29
US23637000P 2000-09-29 2000-09-29
US23636900P 2000-09-29 2000-09-29
US60/236,368 2000-09-29
US60/236,369 2000-09-29
US60/236,367 2000-09-29
US60/236,327 2000-09-29
US60/236,370 2000-09-29
US23703700P 2000-10-02 2000-10-02
US23703800P 2000-10-02 2000-10-02
US23703900P 2000-10-02 2000-10-02
US23680200P 2000-10-02 2000-10-02
US23704000P 2000-10-02 2000-10-02
US60/237,039 2000-10-02
US60/236,802 2000-10-02
US60/237,038 2000-10-02
US60/237,037 2000-10-02
US60/237,040 2000-10-02
US23993700P 2000-10-13 2000-10-13
US23993500P 2000-10-13 2000-10-13
US60/239,937 2000-10-13
US60/239,935 2000-10-13
US24178600P 2000-10-20 2000-10-20
US24122100P 2000-10-20 2000-10-20
US24180900P 2000-10-20 2000-10-20
US24178500P 2000-10-20 2000-10-20
US24178700P 2000-10-20 2000-10-20
US24180800P 2000-10-20 2000-10-20
US24182600P 2000-10-20 2000-10-20
US24096000P 2000-10-20 2000-10-20
US60/241,787 2000-10-20
US60/241,785 2000-10-20
US60/241,808 2000-10-20
US60/241,221 2000-10-20
US60/241,809 2000-10-20
US60/241,826 2000-10-20
US60/240,960 2000-10-20
US60/241,786 2000-10-20
US24461700P 2000-11-01 2000-11-01
US60/244,617 2000-11-01
US24652500P 2000-11-08 2000-11-08
US24647600P 2000-11-08 2000-11-08
US24653200P 2000-11-08 2000-11-08
US24652700P 2000-11-08 2000-11-08
US24647700P 2000-11-08 2000-11-08
US24652600P 2000-11-08 2000-11-08
US24661100P 2000-11-08 2000-11-08
US24661000P 2000-11-08 2000-11-08
US24647400P 2000-11-08 2000-11-08
US24647500P 2000-11-08 2000-11-08
US24652800P 2000-11-08 2000-11-08
US60/246,475 2000-11-08
US60/246,528 2000-11-08
US60/246,532 2000-11-08
US60/246,476 2000-11-08
US60/246,523 2000-11-08
US60/246,478 2000-11-08
US60/246,527 2000-11-08
US60/246,525 2000-11-08
US60/246,477 2000-11-08
US60/246,609 2000-11-08
US60/246,613 2000-11-08
US60/246,524 2000-11-08
US60/246,611 2000-11-08
US60/246,610 2000-11-08
US60/246,474 2000-11-08
US60/246,526 2000-11-08
US60/249,299 2000-11-17
US60/249,208 2000-11-17
US60/249,217 2000-11-17
US60/249,214 2000-11-17
US60/249,264 2000-11-17
US60/249,209 2000-11-17
US60/249,216 2000-11-17
US60/249,210 2000-11-17
US60/249,297 2000-11-17
US60/249,245 2000-11-17
US60/249,218 2000-11-17
US60/249,207 2000-11-17
US60/249,300 2000-11-17
US60/249,265 2000-11-17
US60/249,212 2000-11-17
US60/249,215 2000-11-17
US60/249,244 2000-11-17
US60/249,213 2000-11-17
US60/249,211 2000-11-17
US60/250,160 2000-12-01
US60/250,391 2000-12-01
US60/251,030 2000-12-05
US60/251,988 2000-12-05
US60/256,719 2000-12-05
US60/251,479 2000-12-06
US60/251,868 2000-12-08
US60/251,856 2000-12-08
US60/251,869 2000-12-08
US60/251,989 2000-12-08
US60/251,990 2000-12-08
US60/254,097 2000-12-11
US60/259,678 2001-01-05

Publications (3)

Publication Number Publication Date
WO2001055307A2 WO2001055307A2 (fr) 2001-08-02
WO2001055307A8 true WO2001055307A8 (fr) 2001-09-07
WO2001055307A3 WO2001055307A3 (fr) 2002-01-10

Family

ID=27587117

Family Applications (48)

Application Number Title Priority Date Filing Date
PCT/US2001/001345 WO2001055325A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001325 WO2001055202A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001343 WO2001055323A2 (fr) 2000-01-31 2001-01-17 Acides ncleiques, proteines et anticorps
PCT/US2001/001328 WO2001055316A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001356 WO2001055173A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001239 WO2001055301A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001240 WO2001055302A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001310 WO2001055387A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001322 WO2001055343A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001344 WO2001055324A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001340 WO2001055321A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001313 WO2001055200A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001337 WO2001055205A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001332 WO2001055318A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001359 WO2001055328A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001338 WO2001055367A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et antigenes
PCT/US2001/001327 WO2001055203A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001357 WO2001055208A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001348 WO2001055368A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001351 WO2001055355A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001335 WO2001055319A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001324 WO2001055314A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001326 WO2001055315A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
PCT/US2001/001342 WO2001059064A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001353 WO2001055206A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001330 WO2001055447A1 (fr) 2000-01-31 2001-01-17 Acides nucléiques, proteines et anticorps
PCT/US2001/001308 WO2001055364A2 (fr) 2000-01-31 2001-01-17 Acides nucléiques, protéines et anticorps
PCT/US2001/001306 WO2001055307A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001309 WO2001055308A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001350 WO2001055350A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001302 WO2001055304A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001311 WO2001055309A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001317 WO2001055201A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001301 WO2001055303A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001321 WO2001055312A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001339 WO2001055320A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001358 WO2001055163A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
PCT/US2001/001352 WO2001055327A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001341 WO2001055322A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001315 WO2001055311A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001355 WO2001055207A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001354 WO2001057182A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001312 WO2001054733A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001336 WO2001055204A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001333 WO2001055448A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001316 WO2001054473A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001314 WO2001055310A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001349 WO2001054474A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps

Family Applications Before (27)

Application Number Title Priority Date Filing Date
PCT/US2001/001345 WO2001055325A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001325 WO2001055202A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001343 WO2001055323A2 (fr) 2000-01-31 2001-01-17 Acides ncleiques, proteines et anticorps
PCT/US2001/001328 WO2001055316A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001356 WO2001055173A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001239 WO2001055301A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001240 WO2001055302A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001310 WO2001055387A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001322 WO2001055343A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001344 WO2001055324A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001340 WO2001055321A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001313 WO2001055200A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001337 WO2001055205A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001332 WO2001055318A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001359 WO2001055328A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001338 WO2001055367A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et antigenes
PCT/US2001/001327 WO2001055203A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001357 WO2001055208A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001348 WO2001055368A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001351 WO2001055355A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001335 WO2001055319A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001324 WO2001055314A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001326 WO2001055315A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
PCT/US2001/001342 WO2001059064A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001353 WO2001055206A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001330 WO2001055447A1 (fr) 2000-01-31 2001-01-17 Acides nucléiques, proteines et anticorps
PCT/US2001/001308 WO2001055364A2 (fr) 2000-01-31 2001-01-17 Acides nucléiques, protéines et anticorps

Family Applications After (20)

Application Number Title Priority Date Filing Date
PCT/US2001/001309 WO2001055308A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001350 WO2001055350A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001302 WO2001055304A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001311 WO2001055309A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001317 WO2001055201A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001301 WO2001055303A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001321 WO2001055312A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001339 WO2001055320A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001358 WO2001055163A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
PCT/US2001/001352 WO2001055327A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001341 WO2001055322A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001315 WO2001055311A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001355 WO2001055207A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001354 WO2001057182A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001312 WO2001054733A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001336 WO2001055204A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001333 WO2001055448A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001316 WO2001054473A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001314 WO2001055310A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
PCT/US2001/001349 WO2001054474A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps

Country Status (3)

Country Link
AU (16) AU2001241407A1 (fr)
CA (37) CA2395671A1 (fr)
WO (48) WO2001055325A2 (fr)

Families Citing this family (282)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018435A1 (fr) * 2000-08-28 2002-03-07 Human Genome Sciences, Inc. 18 protéines humaines sécrétées
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6960570B2 (en) 1998-03-18 2005-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6706262B1 (en) 1998-03-18 2004-03-16 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
ATE365800T1 (de) 1998-05-15 2007-07-15 Genentech Inc Therapeutische verwendungen von il-17 homologe polypeptide
US6929938B2 (en) 2001-08-15 2005-08-16 Millennium Pharmaceuticals, Inc. 25501, a human transferase family member and uses therefor
JP2003508011A (ja) * 1999-02-25 2003-03-04 トマス・ジエフアーソン・ユニバーシテイ ヒトｆｅｚ１遺伝子である新規ガン抑制遺伝子に関する組成物、キットおよび方法
US7141417B1 (en) 1999-02-25 2006-11-28 Thomas Jefferson University Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
WO2000050458A1 (fr) * 1999-02-26 2000-08-31 Smithkline Beecham Corporation Clonage du recepteur 7tm (axor 17) du type p2y
AU3885400A (en) * 1999-03-23 2000-10-09 Human Genome Sciences, Inc. 48 human secreted proteins
CA2365601A1 (fr) 1999-03-29 2000-10-05 Kansai Technology Licensing Organization Co., Ltd. Nouvelle cytidine desaminase
ES2355428T3 (es) 1999-08-12 2011-03-25 Agensys, Inc. Antígeno transmembranal de lectina tipo c expresado en cáncer de próstata humano y usos del mismo.
EP1623992A3 (fr) * 1999-09-01 2006-05-10 Genentech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
US7083944B1 (en) * 1999-10-27 2006-08-01 Millennium Pharmaceuticals, Inc. Molecules of the card-related protein family and uses thereof
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
US7005499B1 (en) * 1999-11-18 2006-02-28 Genentech, Inc. Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same
EP1878795A3 (fr) * 1999-11-30 2008-01-23 Genentech, Inc. Compositions et procédés pour le traitement de maladies liées au système immunitaire
EP1666495A1 (fr) * 1999-12-01 2006-06-07 Genentech, Inc. Polypeptides secretés et transmembranaires et acides nucléiques les codant
CN1300781A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽-人shc蛋白43和编码这种多肽的多核苷酸
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US7510855B2 (en) 2000-01-26 2009-03-31 Agensys, Inc. 84P2A9: a prostate and testis specific protein highly expressed in prostate cancer
US6953682B2 (en) 2000-02-10 2005-10-11 Millennium Pharmaceuticals, Inc. Nucleic acid sequences encoding adenylate kinase, phospholipid scramblase-like, DNA fragmentation factor-like, phosphatidylserine synthase-like, and atpase-like molecules and uses therefor
US20020082212A1 (en) * 2000-07-20 2002-06-27 Millennium Pharmaceuticals, Inc. 7716, a novel human ATPase and uses therefor
US7078205B2 (en) 2000-02-17 2006-07-18 Millennium Pharmaceuticals, Inc. Nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, atpase molecules, acyltransferase molecules, pyridoxal-phosphate dependent enzyme molecules and uses therefor
US20020090705A1 (en) * 2000-07-14 2002-07-11 Rachel Meyers 62088, a novel human nucleoside phosphatase family member and uses thereof
US20020055159A1 (en) * 2000-06-15 2002-05-09 Meyers Rachel A. 23680,a novel human aminotransferase and uses therefor
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
JP2003527860A (ja) * 2000-03-23 2003-09-24 イミューソル インコーポレイテッド Ｂｒｃａ−１制御因子およびその使用方法
WO2001073050A2 (fr) 2000-03-24 2001-10-04 Millennium Pharmaceuticals, Inc. 3714, 16742, 23546, et 13887 nouvelles molecules de proteine kinase et leurs utilisations
US20030198953A1 (en) * 2000-03-30 2003-10-23 Spytek Kimberly A. Novel proteins and nucleic acids encoding same
US7632929B2 (en) 2000-04-20 2009-12-15 The Board Of Trustees Of The University Of Arkansas Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof
EP1276873A2 (fr) 2000-04-25 2003-01-22 Lexicon Genetics Incorporated Nouvelles proteines kinases humaines et polynucleotides les codant
EP1280917A2 (fr) * 2000-04-26 2003-02-05 Millennium Pharmaceuticals, Inc. 21657, deshydrogenase humaine a chaine courte et ses utilisations
US6808876B1 (en) 2000-05-02 2004-10-26 Immusol, Inc. Cellular regulators of infectious agents and methods of use
EP1278863A2 (fr) * 2000-05-12 2003-01-29 MERCK PATENT GmbH Nouvelle serine-threonine kinase-4
EP1158001B1 (fr) * 2000-05-26 2007-11-14 F. Hoffmann-La Roche Ag Un acide nucléique produit excessivement dans des cellules tumorales humaines, une protéine codée par ledit acide nucléique et un procédé de diagnose de tumeurs
AU7634301A (en) * 2000-05-26 2001-12-03 Bayer Aktiengesellschaft Regulation of human p78-like serine/threonine kinase
DE10027170A1 (de) * 2000-05-31 2001-12-13 Schering Ag Humanes PEM als Target für die Fertilitätskontrolle
AU6531101A (en) * 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7098311B2 (en) * 2000-06-02 2006-08-29 Brigham And Women's Hospital Fusion of jAZF1 and jjAZ1 genes in endometrial stromal tumors
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6604901A (en) * 2000-06-05 2001-12-17 Bayer Aktiengesellschaft Regulation of human hm74-like g protein coupled receptor
CA2411278A1 (fr) * 2000-06-09 2001-12-20 Corixa Corporation Compositions et procedes pour la therapie et le diagnostic du cancer du colon
US6323016B1 (en) 2000-06-09 2001-11-27 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2001096546A2 (fr) * 2000-06-16 2001-12-20 Incyte Genomics, Inc. Proteine-phosphatases
EP2075253A1 (fr) * 2000-06-23 2009-07-01 Genentech, Inc. Méthodes et composés pour la diagnose et le traitement de troubles associés à l'angiogenèse
EP1325114A2 (fr) * 2000-06-26 2003-07-09 Millennium Pharmaceuticals, Inc. 46619, une nouvelle synthase beta-cetoacyle et utilisations de cette derniere
US7094587B2 (en) 2000-06-27 2006-08-22 Millennium Pharmaceuticals, Inc. 16002 Molecules and uses therefor
AU2001270215A1 (en) * 2000-06-27 2002-01-08 Curagen Corporation Novel polynucleotides and polypeptides encoded thereby
AU2001271621A1 (en) 2000-06-28 2002-01-08 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
AU2001273148A1 (en) * 2000-06-30 2002-01-14 Millennium Pharmaceuticals, Inc. 57658, a human uridine kinase and uses thereof
WO2002004510A2 (fr) * 2000-07-07 2002-01-17 Incyte Genomics, Inc. Proteines liant le nucleotide guanine
JP2004513618A (ja) * 2000-07-07 2004-05-13 インサイト・ゲノミックス・インコーポレイテッド 輸送体及びイオンチャネル
US20030171324A1 (en) * 2000-07-18 2003-09-11 Shyam Ramakrishnan Regulation of human desc1-like serine protease
WO2002006318A2 (fr) * 2000-07-18 2002-01-24 Board Of Regents, The University Of Texas System Procedes et compositions permettant de stabiliser des microtubules et des filaments intermediaires dans des cellules de muscle strie
AU2001273150A1 (en) * 2000-07-20 2002-02-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1303611A2 (fr) * 2000-07-25 2003-04-23 MERCK PATENT GmbH Nouvelle proteine contenant le domaine doigt anneau r1p4
AU2001277200A1 (en) * 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-cad protein and related reagents and methods of use thereof
AU2001277202A1 (en) * 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ras/rerg protein and related reagents and methods of use thereof
EP1657254A3 (fr) * 2000-08-01 2006-06-07 Genentech, Inc. Polypeptide, acides nucléiques le codant, et leur utilisation pour le diagnostic du cancer
US7335732B2 (en) 2000-08-01 2008-02-26 Genentech, Inc. PRO9799 polypeptides
US20020187138A1 (en) * 2000-08-02 2002-12-12 Rachel Meyers 15368, a novel human GTP-releasing factor family member and uses therefor
CA2416732C (fr) 2000-08-02 2016-02-09 Brad St. Croix Profils d'expression de cellules endotheliales
WO2002012330A2 (fr) * 2000-08-04 2002-02-14 Zymogenetics, Inc. Zzp1, proteine humaine secretee
US6943245B2 (en) 2000-08-10 2005-09-13 Board Of Regents, The University Of Texas System Tumor suppressor CAR-1
WO2002014355A2 (fr) * 2000-08-11 2002-02-21 Merck Patent Gmbh Nouvelles protéines mekk
EP1326985A1 (fr) * 2000-08-18 2003-07-16 MERCK PATENT GmbH Identification d'un gene d'acetyltransferase n-terminale humaine
US6706513B2 (en) 2000-08-21 2004-03-16 Bristol-Myers Squibb Company Adenosine deaminase homolog
AU2001285109A1 (en) * 2000-08-21 2002-03-04 Incyte Genomics, Inc. Microtubule-associated proteins and tubulins
AU2001284655A1 (en) * 2000-08-24 2002-03-04 Eli Lilly And Company Nucleic acids, vectors, host cells, polypeptides and uses thereof
US20040096842A1 (en) * 2000-08-28 2004-05-20 Peter Brodin Molecules involved in the regulation of insulin resistance syndrome (irs)
DK1313850T3 (da) 2000-08-28 2008-12-01 Agensys Inc Nucleinsyre og tilsvarende protein med navnet 85PB3 anvendelige til behandling og påvisning af cancer
US20030224396A1 (en) * 2000-08-30 2003-12-04 Yonghong Xiao Regulation of human aminotransferase-like enzyme
AU2001286714A1 (en) * 2000-08-30 2002-03-13 Millennium Pharmaceuticals, Inc. 54370, a novel human sulfate transporter and uses therefor
US20020146800A1 (en) * 2000-08-30 2002-10-10 Curtis Rory A.J. 48921, a novel human GTP releasing factor and uses therefor
AU2002210464A1 (en) * 2000-08-30 2002-03-13 Bayer Aktiengesellschaft Regulation of human aminotransferase-like enzyme
WO2002018582A2 (fr) * 2000-08-31 2002-03-07 Millennium Pharmaceuticals, Inc. 62112, nouvelle deshydrogenase humaine et ses utilisations
MXPA03001930A (es) 2000-09-05 2003-06-19 Amgen Inc Moleculas pseudorreceptoras de factor de necrosis tumoral y uso de las mismas.
EP1364015A2 (fr) * 2000-09-05 2003-11-26 Incyte Genomics, Inc. Molecules pour diagnostic et traitement
WO2002020765A2 (fr) * 2000-09-08 2002-03-14 Millennium Pharmaceuticals, Inc. 38646, nouveau facteur d'echange de guanine nucleotide et ses utilisations
US6372468B1 (en) * 2000-09-14 2002-04-16 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US6391606B1 (en) * 2000-09-14 2002-05-21 Pe Corporation Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof
US20040010119A1 (en) * 2001-02-12 2004-01-15 Xiaojia Guo Novel proteins and nucleic acids encoding same
CA2424199A1 (fr) * 2000-10-05 2002-04-11 Curagen Corporation Nouvelles proteines humaines, polynucleotides codant pour ces proteines et methodes d'utilisation associees
WO2002031126A2 (fr) * 2000-10-11 2002-04-18 Bayer Aktiengesellschaft Regulation d'une peptidyl-prolyl cis-trans isomerase de type cyclophiline humaine
AU2002211597A1 (en) * 2000-10-11 2002-04-22 Millennium Pharmaceuticals, Inc. 8843, a human dual specificity phosphatase family member and uses therefor
US20020064831A1 (en) * 2000-10-12 2002-05-30 The Texas A&M University System Nucleic acid sequences encoding CMG proteins, CMG proteins, and methods for their use
CA2425569A1 (fr) * 2000-10-13 2002-04-18 Eos Biotechnology, Inc. Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate
US6531297B2 (en) * 2000-10-20 2003-03-11 Applera Corporation Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
WO2002062945A2 (fr) 2000-10-25 2002-08-15 Diadexus, Inc. Compositions et techniques relatives a des genes et a des proteines specifiques du poumon
AU2002220668A1 (en) * 2000-10-31 2002-05-15 Bayer Aktiengesellschaft Regulation of human glutathione-s-transferase
AU2002229011A1 (en) * 2000-11-09 2002-05-21 Glaxo Group Limited Deaminase catalyzing the removal of the cyclopropyl moiety from abacavir-mp
EP1349934A2 (fr) 2000-11-20 2003-10-08 Diadexus, Inc. Compositions et methodes relatives a des genes et des proteines specifiques aux seins
AU2001297765A1 (en) * 2000-12-05 2002-10-21 Incyte Genomics, Inc. Ligases
WO2002046477A2 (fr) 2000-12-07 2002-06-13 Chiron Corporation Retrovirus endogenes regules positivement dans le cancer de la prostate
JP2004524825A (ja) 2000-12-07 2004-08-19 ザイモジェネティクス，インコーポレイティド 脂肪細胞補体関連タンパク質ｚａｃｒｐ３ｘ２
WO2002048328A2 (fr) * 2000-12-14 2002-06-20 Pe Corporation (Ny) Proteines kinases humaines isolees, molecules d'acide nucleique codant des proteines kinases humaines et utilisations associees
US20020142376A1 (en) * 2000-12-20 2002-10-03 Gennady Merkulov Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
JP2004536566A (ja) 2000-12-22 2004-12-09 ブリストル−マイヤーズ　スクイブ　カンパニー 小腸において優先的に発現される新規なヒトロイシンリッチリピート含有タンパク質ｈｌｒｒｓｉ１
US6423521B1 (en) 2000-12-28 2002-07-23 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002053591A1 (fr) * 2000-12-30 2002-07-11 Lion Bioscience Ag Cofacteur de recepteur nucleaire mammalien cf12 et ses procedes d'utilisation
AU2002236717A1 (en) * 2001-01-08 2002-07-16 Lexicon Genetics Incorporated Human protease and polynucleotides encoding the same
CA2436661A1 (fr) * 2001-01-30 2002-08-08 Regeneron Pharmaceuticals, Inc. Nouvelles molecules d'acide nucleique et polypeptidiques
EP1637601A3 (fr) * 2001-02-21 2006-03-29 Curagen Corporation Protéines , polynucléotides codant pour ces protéines et procédés d'utilisation
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
WO2002074906A2 (fr) * 2001-03-16 2002-09-26 Eli Lilly And Company Proteines de mammiferes lp et reactifs associes
US7172892B2 (en) 2001-03-22 2007-02-06 Dendreon Corporation Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
US7105333B2 (en) 2001-03-27 2006-09-12 Deadreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
US6913904B2 (en) * 2001-03-27 2005-07-05 Applera Corporation Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
WO2002083860A2 (fr) 2001-04-10 2002-10-24 Agensys, Inc. Acide nucleique et proteine correspondante appelee 151p3d4 utiles dans le traitement et la detection du cancer
EP1383922A4 (fr) 2001-04-10 2005-03-30 Agensys Inc Acide nucleique et proteine correspondante intitule 158p3d2 utiles dans le traitement et la detection du cancer
CA2443123A1 (fr) 2001-04-10 2002-10-24 Agensys, Inc. Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
WO2002086113A2 (fr) * 2001-04-24 2002-10-31 Isis Innovation Ltd Enzyme et marqueur snp pour le depistage d'une maladie
US20040175763A1 (en) * 2001-04-24 2004-09-09 Hiroshi Saito Crohn's disease antibody-binding peptide and method of examining crohn's disease
KR100817467B1 (ko) 2001-05-07 2008-03-31 시오노기세이야쿠가부시키가이샤 혈관신생 마커로서 사용되는 폴리펩티드 및 이의 ｄｎａ
AU2002314048A1 (en) * 2001-05-09 2002-11-18 Bayer Aktiengesellschaft Regulation of human phosphatidic acid phosphatase type 2c-like protein
EP1539942A4 (fr) 2001-05-14 2005-10-19 Dendreon Corp Molecules d'acides nucleiques codant pour une serine protease transmembranaire 10, polypeptides codes et methodes associees
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
AU2002311535A1 (en) * 2001-06-26 2003-01-08 Decode Genetics Ehf. Nucleic acids encoding protein kinases
US20030120040A1 (en) 2001-06-29 2003-06-26 Genentech, Inc. Secreted and Transmembrane polypeptides and nucleic acids encoding the same
GB2399086A (en) * 2001-08-02 2004-09-08 Aeomica Inc Human zinc finger containing gene MDZ4
WO2003031568A2 (fr) * 2001-08-17 2003-04-17 Incyte Genomics, Inc. Molecules de signalisation intracellulaire
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
WO2003023063A1 (fr) * 2001-09-07 2003-03-20 Sankyo Company, Limited Methode d'estimation du risque d'apparition de diabetes
WO2003040369A2 (fr) * 2001-09-17 2003-05-15 Molecular Engines Laboratories Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2003025175A2 (fr) * 2001-09-17 2003-03-27 Molecular Engines Laboratories Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
CA2417455C (fr) 2001-09-28 2008-01-29 Brigham Young University Variants nouveaux de la cyclooxygenase et methodes d'utilisation
US20040248132A1 (en) 2001-10-04 2004-12-09 Toshiyuki Sakai DR5 gene promoter and siah-1 gene promoter
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003031607A1 (fr) * 2001-10-10 2003-04-17 Bayer Healthcare Ag Regulation de deshydrogenase/reductase des chaines courtes humaine
DE60220621T2 (de) 2001-11-09 2008-03-06 Proteologics, Inc. Posh Nukleinsäure, Polypeptide und darauf bezogene Verfahren
US7491690B2 (en) 2001-11-14 2009-02-17 Northwestern University Self-assembly and mineralization of peptide-amphiphile nanofibers
US20050053940A1 (en) * 2001-11-21 2005-03-10 Joh-E Ikeda Huntington's disease gene transcriptional factors
US7151162B2 (en) 2001-12-06 2006-12-19 The University Of Children's Hospital Of Both Cantons Of Basel Nuclear protein
AU2002339697A1 (en) * 2001-12-19 2003-06-30 Genset S.A. Gmg-5 polynucleotides and polypeptides and uses thereof
JP2003245084A (ja) * 2001-12-20 2003-09-02 Morinaga Milk Ind Co Ltd 脳梁又は精子の形成不全の診断及び治療に有用な新規遺伝子、並びにその用途
DE10163467A1 (de) * 2001-12-21 2003-11-27 Axaron Bioscience Ag Protein 24B2 und zugrundliegende DNA-Sequenz
US6759222B2 (en) 2002-01-02 2004-07-06 Millennium Pharmaceuticals, Inc. 14815, a human kinase family member and uses therefor
AU2003202543A1 (en) * 2002-01-07 2003-07-24 Bayer Aktiengesellschaft Human phosphatidic acid phosphatase type 2-like protein
AU2003205611A1 (en) * 2002-01-15 2003-07-30 Medigene Ag Dilated cardiomyopathy associated gene-2 (dcmag-2): a cytoplasmatic inducer of sarcomeric remodeling in cardiomyocytes
WO2003060109A2 (fr) * 2002-01-15 2003-07-24 Bayer Healthcare Ag Regulation d'une subtilase humaine
JPWO2003062429A1 (ja) * 2002-01-23 2005-05-26 山之内製薬株式会社 新規セリンプロテアーゼ
WO2003070749A2 (fr) 2002-02-15 2003-08-28 Northwestern University Auto-assemblage de nanofibres amphiphiles peptidiques dans des conditions physiologiques
EP1338609A1 (fr) * 2002-02-21 2003-08-27 MEMOREC Stoffel GmbH-Medizinisch-Molekulare Entwicklung, Köln Un outre récepteur KDR et son utilisation
EP1497311A2 (fr) * 2002-03-05 2005-01-19 Applera Corporation Proteines transporteuses humaines isolees, molecules d'acide nucleique codant celles-ci, et utilisations associees
AU2003208472A1 (en) * 2002-03-06 2003-09-16 Oxford Glycosciences (Uk) Ltd Novel b-cell malignancy-associated protein
ES2433992T3 (es) 2002-03-13 2013-12-13 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados
US7527935B2 (en) 2002-03-19 2009-05-05 Mitsubishi Tanabe Pharma Corporation G-protein coupled receptor having eicosanoid as ligand and gene thereof
WO2003078466A1 (fr) * 2002-03-19 2003-09-25 Tanabe Seiyaku Co., Ltd. Recepteurs couples a la proteine g et genes correspondants
GB0206684D0 (en) * 2002-03-21 2002-05-01 Babraham Inst Novel proteins
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
US7329502B2 (en) 2002-04-25 2008-02-12 The United States Of America As Represented By The Department Of Health And Human Services ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
JP2004041003A (ja) * 2002-05-17 2004-02-12 Takeda Chem Ind Ltd 新規タンパク質、そのｄｎａおよびその用途
EP2269628A3 (fr) 2002-05-29 2011-04-20 DeveloGen Aktiengesellschaft Proteines specifiques du pancreas
US7198899B2 (en) 2002-06-03 2007-04-03 Chiron Corporation Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers
DK1513934T3 (da) * 2002-06-06 2011-05-02 Oncotherapy Science Inc Gener og polypeptider relateret til humane coloncancersygdomme
US8518694B2 (en) 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
WO2004009626A1 (fr) * 2002-07-22 2004-01-29 Yamanouchi Pharmaceutical Co., Ltd. Nouveau gene associe a l'arthrite rhumatoide
EP1551976B1 (fr) 2002-08-14 2008-12-31 National Institue of Advanced Industrial Science and Technology Nouvelles n-acetylgalactosamine transferases et acides nucleiques codant ces transferases
AU2003243151A1 (en) * 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
WO2004018518A1 (fr) * 2002-08-23 2004-03-04 Japan Science And Technology Agency Peptides antigeniques de tumeur cancereuse solide humains, polynucleotides codant pour ceux-ci et utilisation de ceux-ci
WO2004020662A2 (fr) * 2002-08-27 2004-03-11 Epigenomics Ag Procede et acides nucleiques servant a l'analyse de troubles lies a la proliferation des cellules mammaires
US7452969B2 (en) 2002-08-30 2008-11-18 Licentia Ltd Neurotrophic factor protein and uses thereof
DE60325628D1 (de) 2002-09-30 2009-02-12 Oncotherapy Science Inc Gene und polypeptide in verbindung mit menschlichen pankreaskarzinomen
WO2004035823A2 (fr) * 2002-10-17 2004-04-29 Evotec Neurosciences Gmbh Utilisation diagnostique et therapeutique des gene et proteine ensadin-0625 destinee a des maladies neurodegeneratives
AU2002952216A0 (en) * 2002-10-23 2002-11-07 The Walter And Eliza Hall Institute Of Medical Research Novel therapeutic molecules
US7554021B2 (en) 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
CA2506066A1 (fr) 2002-11-15 2004-06-03 Genomic Health, Inc. Etablissement de profils d'expressions genetique du cancer a recepteur de facteur de croissance epidermique positif
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2003287764B2 (en) * 2002-12-13 2010-01-21 The Walter And Eliza Hall Institute Of Medical Research A novel phosphoprotein
AU2002953341A0 (en) * 2002-12-13 2003-01-09 The Walter And Eliza Hall Institute Of Medical Research A novel phosphoprotein
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
US7326768B2 (en) 2003-02-05 2008-02-05 Juan Saus Goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
EP1445614A1 (fr) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Méthodes d'évaluation in vitro de l'état de progression d'un virus HIV chez un individu
US7074891B2 (en) * 2003-02-07 2006-07-11 Posco Leukocyte stimulating peptides
AU2004213871B9 (en) 2003-02-20 2009-09-03 Genomic Health, Inc. Use of intronic RNA to measure gene expression
EP1600458A4 (fr) * 2003-03-04 2006-10-25 Astellas Pharma Inc Nouveau gene associe a des conditions fibreuses
GEP20094629B (en) 2003-03-19 2009-03-10 Biogen Idec Inc Nogo receptor binding protein
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
ES2488845T5 (es) 2003-06-24 2017-07-11 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
CA2531967C (fr) 2003-07-10 2013-07-16 Genomic Health, Inc. Algorithme de profile d'expression et test du pronostic du cancer
EP2311468B1 (fr) 2003-08-08 2014-01-15 Perseus Proteomics Inc. Gène surexprimé dans le cancer
US20050136434A1 (en) * 2003-08-12 2005-06-23 Mai Xu Isolated heat-inducible cell surface protein and hyperthermia-based tumor immunotargeting therapy
US20070178458A1 (en) * 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II
WO2005026314A2 (fr) * 2003-09-10 2005-03-24 Japan Science And Technology Agency Groupe de genes exprimes de facon differentielle dans des cellules de sang peripherique ainsi que procede de diagnostic et procede d'analyse mettant en oeuvre ce groupe
DE602004028262D1 (de) * 2003-10-02 2010-09-02 Glaxosmithkline Biolog Sa B. pertussis antigene und ihre verwendung bei der vakzinierung
BRPI0414924A (pt) 2003-10-03 2006-11-07 Brigham & Womens Hospital ligantes de tim-3 e seus métodos
WO2005040791A2 (fr) * 2003-10-21 2005-05-06 Bayer Healthcare Ag Diagnostics et therapeutiques pour maladies liees au recepteur de peptides similaire a la somatostatine et a l'angiogenine (salpr)
WO2005051994A2 (fr) * 2003-11-21 2005-06-09 Zymogenetics, Inc. Facteur de necrose tumorale ztnf11
CN1905892A (zh) * 2003-12-05 2007-01-31 西北大学 自组装的肽两亲物和用于生长因子传递的相关方法
AU2004309396B2 (en) 2003-12-23 2010-05-13 Genomic Health, Inc. Universal amplification of fragmented RNA
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
PT3296407T (pt) 2004-03-02 2019-08-23 Univ Johns Hopkins Mutações do gene pik3ca em cancros humanos
TW200539890A (en) 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
WO2005090569A1 (fr) * 2004-03-24 2005-09-29 The Council Of The Queensland Institute Of Medical Research Cancer et acides nucleiques et proteines de testicule vsm1 et vsm2, et leurs utilisations
EP1745069B1 (fr) * 2004-03-30 2009-05-06 Nsgene A/S Utilisation therapeutique du facteur de croissance nsg33
EP1737980A2 (fr) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Marqueurs d'expression genique permettant de predire la reponse a la chimiotherapie
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2005118832A2 (fr) * 2004-06-01 2005-12-15 Bayer Healthcare Ag Agents diagnostiques et therapeutiques pour des maladies associees a une proteine de type kinase regulee par serum/glucocorticoide (sgkl)
RS52593B (en) 2004-06-24 2013-04-30 Biogen Idec Ma Inc. TREATMENT OF THE CONDITIONS CONCERNING DEMYELINIZATION
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
US7985831B2 (en) * 2004-08-05 2011-07-26 Toagosei Co., Ltd. Crohn's disease antibody epitope peptide and reagent for testing Crohn's disease
CA3061785A1 (fr) 2004-11-05 2006-05-18 Genomic Health, Inc. Prediction de reaction a la chimiotherapie au moyen de marqueurs d'expression genique
ATE550440T1 (de) 2004-11-05 2012-04-15 Genomic Health Inc Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung
EP2325207B1 (fr) 2004-11-12 2017-03-15 Xencor, Inc. Variants de fc avec une liaison altérée à fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
MX2007010771A (es) 2005-03-04 2008-03-10 Univ Northwestern Anfifilos peptidicos para union a heparina angiogenicos.
CA2608315C (fr) * 2005-05-13 2014-08-05 Centre National De La Recherche Scientifique Utilisation de nouveau codage genique pour nouvel element de la famille mcm2-8 dans les compositions pharmaceutiques
CA2902070A1 (fr) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Anticorps anti-sp35 et leurs utilisations
EP1907589A4 (fr) * 2005-07-26 2010-11-24 Siemens Healthcare Diagnostics Polymorphismes de nucleotides uniques a susceptibilite par rapport a une maladie cardio-vasculaire
US8207128B2 (en) * 2005-09-28 2012-06-26 Supadelixir Inc. Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereof
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
PL1969003T3 (pl) 2005-12-14 2011-05-31 Herantis Pharma Plc Zastosowanie białka czynnika neurotroficznego
CN101506376A (zh) * 2006-07-03 2009-08-12 埃克森希特医疗股份有限公司 前列腺特异性转录物及其在前列腺癌治疗和诊断中的应用
EP2066810A2 (fr) * 2006-09-08 2009-06-10 Corixa Corporation Procédés, compositions, et kits de détection et de surveillance d'un cancer du colon
US8076295B2 (en) 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
US8999634B2 (en) * 2007-04-27 2015-04-07 Quest Diagnostics Investments Incorporated Nucleic acid detection combining amplification with fragmentation
GB0805159D0 (en) * 2008-03-19 2008-04-23 Sancho Madrid David Immune modulation via C-type lectin
UA101810C2 (ru) 2007-07-27 2013-05-13 Имматикс Биотекнолоджис Гмбх Новые методы иммунотерапии в лечении нейрональных опухолей и опухолей головного мозга
US7863021B2 (en) * 2007-09-05 2011-01-04 Celera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
WO2009034661A1 (fr) * 2007-09-12 2009-03-19 Toppan Printing Co., Ltd. Procédé de diagnostic et induction d'une résistance à un virus
WO2009050309A1 (fr) 2007-10-17 2009-04-23 Universidad De Cordoba Isoformes du récepteur de la somatostatine humaine de type 5 produites par traitement alternatif et paires d'oligonucléotides permettant de les détecter par pcr
EP2235059B1 (fr) 2007-12-26 2015-02-18 Xencor, Inc. Variants de fc avec une liaison altérée à fcrn
GB0803352D0 (en) * 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
EP3112379A1 (fr) * 2008-03-21 2017-01-04 Universiteit Hasselt Biomarqueurs pour la polyarthrite rhumatoïde
EP2982695B1 (fr) 2008-07-09 2019-04-03 Biogen MA Inc. Compositions comprenant des anticorps anti-lingo ou leurs fragments
DK2195013T3 (da) 2008-07-24 2012-02-06 Nsgene As Terapeutisk anvendelse af en vækstfaktor, METRNL
ES2536465T3 (es) 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
US9175353B2 (en) 2008-11-14 2015-11-03 Gen-Probe Incorporated Compositions, kits and methods for detection of campylobacter nucleic acid
WO2010062960A2 (fr) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center Méthodes de détermination d'une réceptivité à une thérapie par anti-tnfα lors d’une maladie intestinale inflammatoire
CA2745849A1 (fr) * 2008-12-09 2010-06-17 Alethia Biotherapeutics Inc. Nouveau variant retroviral endogene humain d'erv3 et utilisations de celui-ci pour diagnostiquer le cancer des ovaires
MX2011010780A (es) 2009-04-13 2011-10-28 Univ Northwestern Andamios novedosos basados en peptido para la regeneracion de cartilagos y metodos para su uso.
WO2011028952A1 (fr) 2009-09-02 2011-03-10 Xencor, Inc. Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
CA2787940C (fr) * 2010-01-27 2020-01-07 Massachusetts Institute Of Technology Agents polypeptidiques techniques pour la neutralisation de la grippe a large spectre ciblee
KR102166408B1 (ko) 2010-09-29 2020-10-16 어젠시스 인코포레이티드 191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
AU2011307488B2 (en) 2010-10-01 2015-08-20 Hoba Therapeutics Aps Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
ES2677699T3 (es) 2010-12-14 2018-08-06 Hananja Ehf Actividad biológica de la proteína placentaria 13
CN104105501B (zh) 2011-09-05 2017-10-20 霍巴治疗公司 异常性疼痛、痛觉过敏、自发性疼痛、和幻痛的治疗
WO2013068445A1 (fr) * 2011-11-09 2013-05-16 Sanofi Diacylglycérol lipase et applications associées
EP3333183B1 (fr) 2012-04-30 2023-02-22 Biocon Limited Protéines de fusion ciblées/immunomodulatrices et leurs procédés de fabrication
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
CA2873623C (fr) 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Antagonistes de lingo-2 pour le traitement d'affections impliquant des neurones moteurs
WO2013174404A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
JP6499079B2 (ja) 2012-11-13 2019-04-10 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
WO2014127785A1 (fr) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
US9023353B2 (en) 2013-03-13 2015-05-05 The Board Of Trustees Of The University Of Arkansas Anti-(+)—methamphetamine monoclonal antibodies
WO2014146672A1 (fr) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
ES2896755T3 (es) 2013-07-11 2022-02-25 Modernatx Inc Composiciones que comprenden polinucleótidos sintéticos que codifican proteínas relacionadas con CRISPR y ARNsg sintéticos y procedimientos de uso
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
RU2715232C2 (ru) 2013-09-25 2020-02-26 Сайтомкс Терапьютикс, Инк. Субстраты матриксной металлопротеиназы и другие расщипляемые фрагменты и способы их использования
WO2015050158A1 (fr) * 2013-10-01 2015-04-09 国立大学法人三重大学 Vaccin d'induction de lymphocytes t contenant une séquence interépitope favorisant une présentation d'antigène
IL294782B2 (en) 2014-01-31 2023-10-01 Cytomx Therapeutics Inc Matriptase and u-plasminogen activator polypeptide substrates and other cleanable moieties, compositions comprising same and uses thereof
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
EP3307070A4 (fr) 2015-06-12 2019-01-02 Emory University Compositions de croissance et de survie pour des cellules capables de produire des anticorps et procédés associés
CN108138198B (zh) 2015-09-04 2022-10-28 合成基因组股份有限公司 为提高的产率而改造的微生物
CN118773299A (zh) 2016-03-17 2024-10-15 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
WO2017172941A2 (fr) * 2016-03-29 2017-10-05 Berz David Modulation de l'entretien structural de l'expression du chromosome-1
US9611297B1 (en) 2016-08-26 2017-04-04 Thrasos Therapeutics Inc. Compositions and methods for the treatment of cast nephropathy and related conditions
US11125757B2 (en) 2017-05-26 2021-09-21 Emory University Methods of culturing and characterizing antibody secreting cells
EP3508499A1 (fr) 2018-01-08 2019-07-10 iOmx Therapeutics AG Anticorps ciblant et d'autres modulateurs d'un gène d'immunoglobuline associé à une résistance contre des réponses immunitaires antitumorales et leurs utilisations
IL283522B2 (en) 2018-12-03 2025-03-01 Agensys Inc Pharmaceutical compositions containing anti-191P4D12 antibody drug conjugates and methods of using them
CN113271956A (zh) 2018-12-06 2021-08-17 西托姆克斯治疗公司 基质金属蛋白酶可裂解的和丝氨酸或半胱氨酸蛋白酶可裂解的底物及其使用方法
AU2020261435A1 (en) * 2019-04-26 2021-11-25 Sangamo Therapeutics, Inc. Engineering AAV
AU2020311579A1 (en) 2019-07-05 2022-02-03 Iomx Therapeutics Ag Antibodies binding IgC2 of IGSF11 (VSIG3) and uses thereof
WO2021083958A1 (fr) * 2019-10-29 2021-05-06 Specialites Pet Food Nouveaux peptides induisant la satiété
US20240376165A1 (en) * 2020-03-27 2024-11-14 Onecuregen Co., Ltd. Composition comprising vgll1 peptide for treatment of cancer
US20230212243A1 (en) * 2020-05-12 2023-07-06 Institut Curie Neoantigenic Epitopes Associated with SF3B1 Mutations
WO2021229502A1 (fr) 2020-05-15 2021-11-18 Crispr Therapeutics Ag Arn messager codant pour cas9 destiné à être utilisé dans des systèmes d'édition du génome
EP4175668A1 (fr) 2020-07-06 2023-05-10 iOmx Therapeutics AG Anticorps de liaison à l'igv d'igsf11 (vsig3) et leurs utilisations
KR20230147078A (ko) * 2021-01-21 2023-10-20 에라스무스 유니버시티 메디컬 센터 로테르담 치료에 사용하기 위한 t 세포
EP4294403A4 (fr) * 2021-02-18 2024-12-11 Beren Therapeutics P.B.C. Méthodes de traitement de l'hypercholestérolémie familiale hétérozygote et homozygote avec des cyclodextrines
WO2023225602A1 (fr) * 2022-05-20 2023-11-23 Medikine, Inc. Polypeptides de liaison au récepteur de l'interleukine-18 et leurs utilisations

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446240A (en) * 1981-01-30 1984-05-01 Nerenberg Samuel T Pancreas specific protein systems
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US6080540A (en) * 1990-04-20 2000-06-27 Cold Spring Harbor Laboratory Cloning of mammalian genes in microbial organisms and methods for pharmacological screening
CA2096975C (fr) * 1990-11-26 2003-04-22 Carl Wu Facteurs de transcription des contraintes subies par les cellules
US5721352A (en) * 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
US5840870A (en) * 1995-12-29 1998-11-24 Incyte Pharmaceuticals, Inc. Polynucleotides PANC1A and PANC1B associated with pancreatic cancer
US5912160A (en) * 1995-08-22 1999-06-15 Thomas Jefferson University Gab1, Grb2 binding protein, and compositions for making and methods of using the same
JP3462313B2 (ja) * 1995-08-24 2003-11-05 キッコーマン株式会社 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体ｄｎａ及び変異型ウリカーゼの製造法
US5998165A (en) * 1995-12-29 1999-12-07 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a protein associated with pancreatic cancer
WO1997040855A1 (fr) * 1996-04-29 1997-11-06 The Johns Hopkins University School Of Medicine Regulateur de la degradation de l'arn chez les mammiferes induite par des transcrits non-sens
US6500934B1 (en) * 1996-07-24 2002-12-31 Michael Rush Lerner Bivalent agonists for G-protein coupled receptors
US5976834A (en) * 1997-01-09 1999-11-02 Smithkline Beecham Corporation cDNA clone HNFJD15 that encodes a novel human 7-transmembrane receptor
US5925521A (en) * 1997-03-31 1999-07-20 Incyte Pharmaceuticals, Inc. Human serine carboxypeptidase
CA2232743A1 (fr) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation Tl5, homologue tnf
WO1998045435A2 (fr) * 1997-04-10 1998-10-15 Genetics Institute, Inc. MARQUEURS SECRETES DE SEQUENCE EXPRIMEE (sEST)
IT1291110B1 (it) * 1997-04-15 1998-12-29 Istituto Europ Di Oncologia S Interattori intracellulari e specificita' di legame del dominio eh
US5948641A (en) * 1997-05-29 1999-09-07 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a metal response element binding protein
EP1012292A1 (fr) * 1997-06-06 2000-06-28 Regeneron Pharmaceuticals, Inc. Element ntn-2 de la famille des ligands du tnf
AU9484398A (en) * 1997-09-17 1999-04-05 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US5932442A (en) * 1997-09-23 1999-08-03 Incyte Pharmaceuticals, Inc. Human regulatory molecules
US5972660A (en) * 1997-10-22 1999-10-26 Incyte Pharmaceuticals, Inc. Human hydroxypyruvate reductase
DE19818598A1 (de) * 1998-04-19 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Pankreasnormalgewebe
AU758074B2 (en) * 1998-04-29 2003-03-13 Genesis Research And Development Corporation Limited Polynucleotides isolated from skin cells and methods for their use
US6262249B1 (en) * 1998-06-23 2001-07-17 Chiron Corporation Pancreatic cancer genes
CA2296792A1 (fr) * 1999-02-26 2000-08-26 Genset S.A. Sequences marqueurs exprimees et proteines humaines codees

Also Published As

Publication number Publication date
WO2001055327A8 (fr) 2001-09-07
WO2001055308A3 (fr) 2002-07-04
WO2001057182A3 (fr) 2002-03-28
WO2001055387A8 (fr) 2001-12-06
WO2001055325A8 (fr) 2001-12-13
WO2001055387A1 (fr) 2001-08-02
WO2001055208A1 (fr) 2001-08-02
WO2001055311A2 (fr) 2001-08-02
WO2001055173A8 (fr) 2001-11-29
WO2001055320A2 (fr) 2001-08-02
WO2001055321A3 (fr) 2002-07-04
CA2395816A1 (fr) 2001-08-02
WO2001055208A8 (fr) 2001-09-07
WO2001055367A1 (fr) 2001-08-02
WO2001055367A8 (fr) 2001-12-20
AU4313701A (en) 2001-08-14
CA2392757A1 (fr) 2001-08-02
WO2001055364A8 (fr) 2001-09-07
CA2395872A1 (fr) 2001-08-02
CA2395295A1 (fr) 2001-08-02
WO2001055315A3 (fr) 2002-02-07
WO2001055324A8 (fr) 2001-09-07
WO2001055368A1 (fr) 2001-08-02
CA2392751A1 (fr) 2001-08-02
WO2001054473A2 (fr) 2001-08-02
WO2001055303A8 (fr) 2001-09-07
WO2001055323A2 (fr) 2001-08-02
AU2001241407A1 (en) 2001-08-07
WO2001055322A8 (fr) 2001-09-07
WO2001055368A8 (fr) 2001-09-07
WO2001054474A8 (fr) 2001-12-20
WO2001055343A8 (fr) 2001-09-07
WO2001055310A8 (fr) 2001-09-07
AU2001241416A1 (en) 2001-08-07
WO2001055301A2 (fr) 2001-08-02
CA2393652A1 (fr) 2001-08-02
WO2001055314A3 (fr) 2002-05-02
WO2001055322A2 (fr) 2001-08-02
WO2001055355A1 (fr) 2001-08-02
WO2001055447A8 (fr) 2001-09-07
WO2001055321A2 (fr) 2001-08-02
WO2001055301A3 (fr) 2009-06-04
CA2394039A1 (fr) 2001-08-02
WO2001054733A8 (fr) 2001-09-07
WO2001055203A1 (fr) 2001-08-02
CA2392428A1 (fr) 2001-08-02
WO2001055318A3 (fr) 2002-07-04
WO2001055307A3 (fr) 2002-01-10
WO2001055163A8 (fr) 2001-09-07
WO2001055320A8 (fr) 2001-09-07
AU2001241408A1 (en) 2001-08-07
WO2001055318A8 (fr) 2001-09-07
AU2001250770A1 (en) 2001-08-07
AU2001241406A1 (en) 2001-08-07
WO2001055202A1 (fr) 2001-08-02
AU4141101A (en) 2001-08-20
CA2393002A1 (fr) 2001-08-02
WO2001055207A1 (fr) 2001-08-02
WO2001055315A2 (fr) 2001-08-02
WO2001055350A8 (fr) 2001-09-07
WO2001055304A8 (fr) 2001-09-07
WO2001055328A3 (fr) 2002-07-04
WO2001054474A2 (fr) 2001-08-02
CA2395398A1 (fr) 2001-08-02
WO2001055303A3 (fr) 2001-12-20
WO2001055316A2 (fr) 2001-08-02
WO2001055200A1 (fr) 2001-08-02
WO2001055319A8 (fr) 2001-09-07
WO2001055343A1 (fr) 2001-08-02
CA2395654A1 (fr) 2001-08-02
WO2001055303A2 (fr) 2001-08-02
WO2001055448A1 (fr) 2001-08-02
WO2001055447A1 (fr) 2001-08-02
WO2001055163A1 (fr) 2001-08-02
CA2392450A1 (fr) 2001-08-16
CA2395699A1 (fr) 2001-08-02
WO2001055202A8 (fr) 2001-09-07
AU2001241409A1 (en) 2001-08-07
WO2001055318A2 (fr) 2001-08-02
CA2395724A1 (fr) 2001-08-02
WO2001055205A8 (fr) 2001-12-13
WO2001055309A8 (fr) 2001-09-07
CA2395666A1 (fr) 2001-08-02
WO2001055312A8 (fr) 2001-09-07
WO2001055325A2 (fr) 2001-08-02
CA2395738A1 (fr) 2002-08-02
CA2395734A1 (fr) 2001-08-02
CA2395178A1 (fr) 2001-08-02
CA2395849A1 (fr) 2001-08-02
WO2001055308A2 (fr) 2001-08-02
CA2392422A1 (fr) 2001-08-02
CA2395729A1 (fr) 2001-08-02
AU2001241412A1 (en) 2001-08-07
WO2001055320A3 (fr) 2002-04-11
CA2395787A1 (fr) 2001-08-02
WO2001055311A8 (fr) 2001-09-07
CA2393912A1 (fr) 2001-08-02
WO2001055302A2 (fr) 2001-08-02
AU2001241405A1 (en) 2001-08-07
WO2001055364A2 (fr) 2001-08-02
CA2393618A1 (fr) 2001-08-02
WO2001055319A3 (fr) 2002-02-21
CA2398411A1 (fr) 2001-08-02
AU2001241414A1 (en) 2001-08-07
AU2001241410A1 (en) 2001-08-07
WO2001055203A8 (fr) 2001-09-07
WO2001055309A3 (fr) 2002-07-18
AU2001241418A1 (en) 2001-08-07
WO2001054733A1 (fr) 2001-08-02
WO2001055304A2 (fr) 2001-08-02
WO2001055304A3 (fr) 2002-07-18
WO2001055319A2 (fr) 2001-08-02
WO2001055310A2 (fr) 2001-08-02
WO2001055355A8 (fr) 2001-09-07
CA2395885A1 (fr) 2001-08-02
AU2001241415A1 (en) 2001-08-07
WO2001055200A8 (fr) 2001-09-07
WO2001055327A2 (fr) 2001-08-02
CA2395858A1 (fr) 2001-08-02
WO2001055322A3 (fr) 2002-07-04
WO2001055302A3 (fr) 2002-02-14
WO2001055323A3 (fr) 2002-05-10
WO2001055312A3 (fr) 2002-03-14
WO2001055328A8 (fr) 2001-09-07
WO2001055311A3 (fr) 2002-07-04
CA2397407A1 (fr) 2001-08-02
WO2001055307A2 (fr) 2001-08-02
WO2001055308A8 (fr) 2001-09-07
WO2001055309A2 (fr) 2001-08-02
WO2001055324A2 (fr) 2001-08-02
WO2001055314A2 (fr) 2001-08-02
WO2001055323A8 (fr) 2001-09-07
WO2001057182A2 (fr) 2001-08-09
CA2395671A1 (fr) 2001-08-02
WO2001055325A3 (fr) 2002-07-04
WO2001055206A1 (fr) 2001-08-02
WO2001055328A2 (fr) 2001-08-02
WO2001055314A8 (fr) 2001-09-07
CA2395827A1 (fr) 2001-08-02
WO2001055448A8 (fr) 2001-09-07
WO2001055205A1 (fr) 2001-08-02
WO2001055204A8 (fr) 2001-09-07
WO2001055327A3 (fr) 2002-02-28
WO2001055310A3 (fr) 2001-12-27
WO2001054473A8 (fr) 2001-09-07
WO2001055350A1 (fr) 2001-08-02
WO2001055312A2 (fr) 2001-08-02
WO2001055207A8 (fr) 2001-09-07
WO2001055321A8 (fr) 2001-09-07
WO2001055316A3 (fr) 2002-04-11
WO2001055204A1 (fr) 2001-08-02
WO2001055324A3 (fr) 2002-01-24
WO2001059064A2 (fr) 2001-08-16
WO2001055201A8 (fr) 2001-09-07
AU2001241417A1 (en) 2001-08-07
WO2001055301A8 (fr) 2001-09-07
CA2395693A1 (fr) 2001-08-02
WO2001055302A8 (fr) 2001-09-07
CA2397839A1 (fr) 2001-08-02
WO2001055316A8 (fr) 2001-09-07
CA2392438A1 (fr) 2001-08-02
CA2395403A1 (fr) 2001-08-02
WO2001059064A3 (fr) 2002-03-14
WO2001055173A2 (fr) 2001-08-02
WO2001055315A8 (fr) 2001-09-07
AU2001241413A1 (en) 2001-08-07
WO2001055364A3 (fr) 2002-07-04
CA2394841A1 (fr) 2001-08-02
CA2398877A1 (fr) 2001-08-09
CA2392398A1 (fr) 2001-08-02
WO2001055206A8 (fr) 2001-12-13
WO2001055201A1 (fr) 2001-08-02

Similar Documents

Publication Publication Date Title
WO2001055307A3 (fr) Acides nucleiques, proteines et anticorps
WO2001090304A3 (fr) Acides nucleiques, proteines et anticorps
WO2001054472A3 (fr) Acides nucleiques, proteines et anticorps
WO2001055306A3 (fr) Acides nucleiques, proteines, et anticorps
WO2001055326A8 (fr) Acides nucleiques, proteines et anticorps
WO2001055168A8 (fr) Acides nucleiques, proteines, et anticorps
WO2001055440A8 (fr) Acides nucleiques, proteines et anticorps
WO2002072763A3 (fr) Acides nucleiques, proteines et anticorps
WO2001055167A8 (fr) Acides nucleiques, proteines et anticorps
WO2001055162A8 (fr) Acides nucleiques, proteines et anticorps
WO2001055449A8 (fr) Acides nucleiques, proteines et anticorps
WO2001055305A3 (fr) Acides nucleiques, proteines, et anticorps

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 31/2001 UNDER "PUBLISHED", ADD "WITH SEQUENCE LISTING PART OF DESCRIPTION PUBLISHED SEPARATELY IN ELECTRONIC FORM AND AVAILABLE UPON REQUEST FROM THE INTERNATIONAL BUREAU."

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001908611

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001908611

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001908611

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载